Low serum CTRP3 is related to more severe distal symmetric polyneuropathy in type 2 diabetes patients

被引:1
|
作者
Han, Pingping [1 ,3 ]
Hu, Fan [1 ]
Guo, Jia [1 ,3 ]
Xu, Leirui [1 ,3 ]
Zhang, Junxia [2 ]
机构
[1] Chinese PLA, Cent Theater Command Gen Hosp, Dept Endocrinol, Wuhan 430070, Peoples R China
[2] TaiKang Tongji Wuhan Hosp, Dept Endocrinol, Wuhan 430030, Hubei, Peoples R China
[3] Wuhan Univ Sci & Technol, Coll Med, Wuhan 430065, Hubei, Peoples R China
关键词
C1q tumor necrosis factor-related protein 3 (CTRP3); Type 2 diabetes mellitus; Distal symmetric polyneuropathy (DSPN); NSS score; NDS score; C1Q/TNF-RELATED PROTEIN-3 CTRP3; INSULIN SENSITIVITY; OXIDATIVE STRESS; INFLAMMATION; NEUROPATHY; ADIPOKINE; OBESITY;
D O I
10.1007/s42000-024-00592-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Distal symmetric polyneuropathy (DSPN) is one of the most common chronic complications in patients with type 2 diabetes mellitus (T2DM). Our previous study found that serum C1q tumor necrosis factor-related protein 3 (CTRP3) levels were decreased in type 2 diabetic patients. Thus, this study was designed to reveal the relationship between low serum CTRP3 and the prevalence and severity of DSPN. Methods A total of 178 cases of patients with T2DM were enrolled in the study. The subjects were divided into the DSPN group (n = 89) and the non-DSPN group (n = 89). Both anthropometric parameters and neurologic symptoms were recorded. Furthermore, neurologic signs, the neuropathy symptom score (NSS), and the neuropathy disability score (NDS) were assessed. Biochemical indexes, fasting insulin, and C peptide were measured. Serum CTRP3 concentrations were assayed using the ELISA method. Results Serum CTRP3 levels decreased significantly in the DSPN group compared with the non-DSPN group (P < 0.05). CTRP3 was negatively associated with the number of positive signs, NSS score, and NDS score in patients with DSPN (all P < 0.05). Interestingly, the higher the NSS score or NDS score, the lower were the levels of serum CTRP3 (all P < 0.05). Moreover, patients with lower CTRP3 levels (< 7.58ng/ml) had a higher rate of neurologic signs (all P < 0.05). Binary logistic regression analysis showed that CTRP3 independently predicted the occurrence of DSPN (beta = -0.316, P < 0.001). ROC curve analysis revealed that the best cut-off value of CTRP3 for the prediction of DSPN was 7.55ng/ml (sensitivity 78.7%, specificity 79.8%), the area under the curve (AUC) was 0.763 (95% CI 0.689-0.838, P < 0.001). Conclusion Low serum CTRP3 could be a predictor for the occurrence and progression of DSPN in Chinese patients with T2DM.
引用
收藏
页码:99 / 107
页数:9
相关论文
共 50 条
  • [1] Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease it in patients with type 2 diabetes mellitus
    Zhang, Junxia
    Zhang, Bilin
    Cheng, Yangyang
    Xu, Jinxiu
    CYTOKINE, 2018, 106 : 131 - 135
  • [2] Low Serum Cartonectin/CTRP3 Concentrations in Newly Diagnosed Type 2 Diabetes Mellitus: In Vivo Regulation of Cartonectin by Glucose
    Ban, Bo
    Bai, Bo
    Zhang, Manman
    Hu, Jiamiao
    Ramanjaneya, Manjunath
    Tan, Bee K.
    Chen, Jing
    PLOS ONE, 2014, 9 (11):
  • [3] Temporal Trends in Distal Symmetric Polyneuropathy in Type 2 Diabetes: The Fremantle Diabetes Study
    Davis, Wendy A.
    Hamilton, Emma
    Davis, Timothy M. E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (03): : e1083 - e1094
  • [4] Accuracy of the Neuropad Test for the Diagnosis of Distal Symmetric Polyneuropathy in Type 2 Diabetes
    Papanas, Nikolaos
    Paschos, Paschalis
    Papazoglou, Dimitrios
    Papatheodorou, Konstantinos
    Paletas, Konstantinos
    Maltezos, Efstratios
    Tsapas, Apostolos
    DIABETES CARE, 2011, 34 (06) : 1378 - 1382
  • [5] Phenylacetylglutamine as a novel biomarker of type 2 diabetes with distal symmetric polyneuropathy by metabolomics
    J. Xu
    M. Cai
    Z. Wang
    Q. Chen
    X. Han
    J. Tian
    S. Jin
    Z. Yan
    Y. Li
    B. Lu
    H. Lu
    Journal of Endocrinological Investigation, 2023, 46 : 869 - 882
  • [6] Phenylacetylglutamine as a novel biomarker of type 2 diabetes with distal symmetric polyneuropathy by metabolomics
    Xu, J.
    Cai, M.
    Wang, Z.
    Chen, Q.
    Han, X.
    Tian, J.
    Jin, S.
    Yan, Z.
    Li, Y.
    Lu, B.
    Lu, H.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2023, 46 (05) : 869 - 882
  • [7] Low serum bilirubin levels contribute to the presence and progression of distal symmetrical polyneuropathy in Chinese patients with type 2 diabetes
    Jin, J.
    Wang, W.
    Gu, T.
    Chen, C.
    Sun, J.
    Chen, W.
    Bi, Y.
    Zhu, D.
    DIABETES & METABOLISM, 2019, 45 (01) : 47 - 52
  • [8] Ctrp3, a new anti-inflammatory and cardioprotective adipokine in patients with cardiovascular diseases and type 2 diabetes
    Kratochvilova, H.
    Kasperova, B. J.
    Lacinova, Z.
    Lankova, I.
    Trnovska, J.
    Netuka, I.
    Ivak, P.
    Mahrik, J.
    Hlavacek, D.
    Mraz, M.
    Haluzik, M.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S255 - S255
  • [9] Distal Symmetric Polyneuropathy Identification in Type 2 Diabetes Subjects: A Random Forest Approach
    Maeda-Gutierrez, Valeria
    Galvan-Tejada, Carlos E.
    Cruz, Miguel
    Valladares-Salgado, Adan
    Galvan-Tejada, Jorge, I
    Gamboa-Rosales, Hamurabi
    Garcia-Hernandez, Alejandra
    Luna-Garcia, Huizilopoztli
    Gonzalez-Curiel, Irma
    Martinez-Acuna, Monica
    HEALTHCARE, 2021, 9 (02)
  • [10] Impact of Plasma Xanthine Oxidoreductase Activity on the Mechanisms of Distal Symmetric Polyneuropathy Development in Patients with Type 2 Diabetes
    Fujishiro, Midori
    Ishihara, Hisamitsu
    Ogawa, Katsuhiko
    Murase, Takayo
    Nakamura, Takashi
    Watanabe, Kentaro
    Sakoda, Hideyuki
    Ono, Hiraku
    Yamamotoya, Takeshi
    Nakatsu, Yusuke
    Asano, Tomoichiro
    Kushiyama, Akifumi
    BIOMEDICINES, 2021, 9 (08)